First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Published:2021-10-16 Issue:11 Volume:41 Page:999-1010
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Wang Lu,Lu Jinmiao,Zhou Sufeng,Zhao Yuqing,Xie Lijun,Zhou Chen,Chen Juan,Ding Sijia,Xie Daosheng,Ding Juping,Yu Qiang,Shen Hong,Hao Guangtao,Shao Feng

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01088-5.pdf

Reference19 articles.

1. International Diabetes Federation. IDF diabetes atlas. 9th ed. 2019. https://diabetesatlas.org/en/. Accessed 7 Oct 2019.

2. Wang X, Li X, Qie S, Zheng Y, Liu Y, Liu G. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Medicine (Baltimore). 2018;97(34): e11946. https://doi.org/10.1097/MD.0000000000011946.

3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705. https://doi.org/10.1016/S0140-6736(06)69705-5.

4. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet. 2008;47(7):417–48. https://doi.org/10.2165/00003088-200847070-00001.

5. Gou ZP, Wang ZL, Liang XF, Zheng L, Wang Y, Feng P. Single-dose escalation study of yogliptin in healthy Chinese volunteers. Eur J Pharm Sci. 2019;136: 104950. https://doi.org/10.1016/j.ejps.2019.06.004.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in small-molecule insulin secretagogues for diabetes treatment;Biomedicine & Pharmacotherapy;2024-09

2. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM);European Journal of Medicinal Chemistry;2024-06

3. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus;Frontiers in Endocrinology;2024-03-11

4. A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy;Diabetes, Obesity and Metabolism;2023-09-19

5. Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled phase 3 trial;Diabetes, Obesity and Metabolism;2023-09-03